目的 评价肝复乐胶囊联合索拉非尼治疗晚期肝癌的临床疗效。方法 选取2014年5月—2016年5月在中国人民解放军总医院第一附属医院接受治疗的晚期肝癌患者80例，根据治疗方案的差别分成对照组（40例）和治疗组（40例）。对照组患者口服甲苯磺酸索拉非尼片，0.4 g/次，2次/d。治疗组在对照组的基础上口服肝复乐胶囊，6粒/次，3次/d。两组患者均治疗4周。评价两组患者治疗前后近期疗效、生存质量改善情况和血清学指标差异。结果 治疗后，对照组的客观缓解率（ORR）为40.00%，临床获益率（CBR）为75.00%，治疗组的ORR为67.50%，CBR为92.50%，两组ORR、CBR比较差异均有统计学意义（P < 0.05）。治疗后，对照组的生存质量改善率为75.00%，显著低于治疗组的92.50%，两组生存质量改善情况比较差异有统计学意义（P < 0.05）。治疗后，两组患者血清血管内皮生长因子（VEGF）、缺氧诱导因子-1α（HIF-1α）和骨桥蛋白（OPN）水平均明显降低，同组治疗前后比较差异具有统计学意义（P < 0.05）；且治疗后治疗组患者降低更明显，两组比较差异具有统计学意义（P < 0.05）。结论 肝复乐胶囊联合索拉非尼治疗晚期肝癌的临床疗效较好，可以提高患者免疫能力和改善生活质量，具有一定的临床推广应用价值。

Objective To evaluate the clinical effect of Ganfule Capsules combined with sorafenib in treatment of advanced liver cancer. Methods Patients (80 cases) with advanced liver cancer in First Affiliated Hospital of PLA General Hospital from May 2014 to May 2016 were divided into control (40 cases) and treatment (40 cases) groups according to different treatments. Patients in the control group were po administered with Sorafenib Tosylate Tablets, 0.4 g/time, twice daily. Patients in the treatment group were po administered with Ganfule Capsules on the basis of the control group, 6 grains/time, three times daily. Patients in two groups were treated for four weeks. After treatment, the differences of the clinical efficacy, short-term efficacy, quality of life, and serological indexes in two groups were evaluated. Results ORR and CBR in the control group were 40.00% and 75.00% respectively, and ORR and CBR in the treatment were 67.50% and 92.50% respectively, and there were differences between two groups (P < 0.05). After treatment, the improvement rate of life quality in the control group was 75.00%, which was significantly lower than 92.50% in the treatment group, with significant difference between two groups (P < 0.05). After treatment, the serum VEGF, HIF-1α, and OPN levels in two groups significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these serological indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Ganfule Capsules combined with sorafenib has a good clinical curative effect in treatment of advanced liver cancer, can improve the immune ability and the quality of life, which has a certain clinical application value.